1. Clinical & Scientific Overview
Betahistine Dihydrochloride, Cinnarizine & Flunarizine (TIP-MED-000291, Reference Code [5.8]-CMP21) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Synthetic Non-Absorbable Disaccharide (Galactose-Fructose); Osmotic Laxative & Hepatic Encephalopathy Ammonia Detoxifier.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed per approved Author Decision DEC-08 (Option 8A; displaced HTML [11.28]). Vestibular vertigo and Meniere's comparisons: Betahistine (Vertin 8/16/24 mg), Cinnarizine (Stugeron 25/75 mg), and Flunarizine (Sibelium 5/10 mg).
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Co-indexed per approved Author Decision DEC-08 (Option 8A; displaced HTML [11.28]). Vestibular vertigo and Meniere's comparisons: Betahistine (Vertin 8/16/24 mg), Cinnarizine (Stugeron 25/75 mg), and Flunarizine (Sibelium 5/10 mg).
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic constipation (especially in elderly, opioid-induced, post-surgical/haemorrhoidectomy, and pregnancy)
- prevention and treatment of portal-systemic hepatic encephalopathy in liver cirrhosis (colonic bacteria ferment lactulose to lactic/acetic acid, lowering colonic pH to ~5
- 0 and trapping diffusible NH3 as non-absorbable ammonium ion NH4+)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-08 (Option 8A; displaced HTML [11.28]). Vestibular vertigo and Meniere's comparisons: Betahistine (Vertin 8/16/24 mg), Cinnarizine (Stugeron 25/75 mg), and Flunarizine (Sibelium 5/10 mg).
Administration & Meal Timing: With or without food; may be mixed with water, milk, or fruit juice to mask the intensely sweet taste. | Constipation: Once daily at bedtime (onset of bowel movement takes 24 to 48 hours). Hepatic Encephalopathy: 3–4 times daily.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [5.8].
Renal: Negligible systemic absorption; safe in CKD, though monitor electrolytes if diarrhoea develops. Hepatic: Cornerstone therapy in decompensated hepatic cirrhosis!
Renal: Negligible systemic absorption; safe in CKD, though monitor electrolytes if diarrhoea develops. Hepatic: Cornerstone therapy in decompensated hepatic cirrhosis!
Renal: Negligible systemic absorption; safe in CKD, though monitor electrolytes if diarrhoea develops. Hepatic: Cornerstone therapy in decompensated hepatic cirrhosis!
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in galactosaemia, complete gastrointestinal obstruction, or digestive perforation. Caution in patients with lactose intolerance (syrup contains small residual amounts of free galactose and lactose).
Key Clinical Precautions: Renal: Negligible systemic absorption; safe in CKD, though monitor electrolytes if diarrhoea develops. Hepatic: Cornerstone therapy in decompensated hepatic cirrhosis!
8. Adverse Effects Profile
- Abdominal flatulence, bloating, intestinal cramping, and belching during the first few days (due to bacterial gas production—usually subsides), dose-dependent osmotic diarrhoea.
- Hypernatraemia, hypokalaemia, and severe dehydration if excessive high-dose diarrhoea occurs (especially in elderly encephalopathic patients who cannot drink water freely).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Broad-spectrum oral antibiotics (neomycin, metronidazole, ciprofloxacin) may alter colonic saccharolytic flora, theoretically reducing acidification (though rifaximin + lactulose is standard synergistic therapy in hepatic encephalopathy)
- Oral antacids inhibit the drop in colonic pH
- Diuretic-induced hypokalaemia is worsened by lactulose-induced diarrhoea (increasing digoxin toxicity)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [5.8].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Inform patients using lactulose for constipation that it is a gentle stool softener that takes 1 to 2 days (24–48 hours) to start working—it is not an overnight stimulant purge. Drink a full glass of water after taking the measured dose cup. In cirrhosis caregivers, explain that passing 2–3 soft stools daily is the exact goal that keeps toxic ammonia out of the brain.
- Meal & Clock Timing Instruction: With or without food; may be mixed with water, milk, or fruit juice to mask the intensely sweet taste. (Constipation: Once daily at bedtime (onset of bowel movement takes 24 to 48 hours). Hepatic Encephalopathy: 3–4 times daily.)
- Missed Dose Protocol: Take as soon as remembered; skip if close to next dose. Never double.
- Geriatric Dispensing Pearl: Safe long-term laxative in elderly patients; monitor closely for dehydration and hypernatraemia if watery diarrhoea(>3 stools/day) develops.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Solution / Syrup: 10 g / 15 mL (667 mg/mL) in 100 mL, 200 mL, 450 mL bottles
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.15]-C27 Acotiamide — Peripheral D2 Antagonist + Acetylcholinesterase Inhibitor Gastrop
- [5.17]-C28 Liquid Paraffin Emulsions — Bulk-Forming Soluble Fibre Laxative & Faecal Lubricant/Osmotic Co
- [5.18]-C29 Racecadotril — Peripheral Mu-Opioid Antidiarrhoeal & Antisecretory Enkephalinase
- [5.19]-C30 Zinc Sulphate Co-Intervention — Physiological Glucose–Sodium Co-Transport Rehydration Solution (O
